Pemetrexed, a Novel Antifolate Therapeutic Alternative for Cancer Chemotherapy
- 1 May 2006
- journal article
- review article
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 26 (5), 641-654
- https://doi.org/10.1592/phco.26.5.641
Abstract
No abstract availableKeywords
This publication has 48 references indexed in Scilit:
- FDA Drug Approval Summaries: Pemetrexed (Alimta®)The Oncologist, 2004
- Enter Alimta®: A New Generation AntifolateThe Oncologist, 2004
- Thymidine Rescue: An Antidote for Pemetrexed-Related Toxicity in the Setting of Acute Renal FailureJournal of Clinical Oncology, 2003
- Pemetrexed (Alimta®): a novel multitargeted antifolate agentExpert Review of Anticancer Therapy, 2003
- Molecular, biochemical, and cellular pharmacology of pemetrexedSeminars in Oncology, 2002
- Folate status and the safety profile of antifolates.Seminars in Oncology, 2002
- Multiple folate enzyme inhibition: mechanism of a novel pyrrolopyrimidine-based antifolate LY231514 (MTA)Advances in Enzyme Regulation, 1998
- Preoperative Tumor Volume Is Associated With Outcome In Malignant Pleural MesotheliomaThe Journal of Thoracic and Cardiovascular Surgery, 1998
- Folic Acid AntagonistsAnnals of Internal Medicine, 1963
- Temporary Remissions in Acute Leukemia in Children Produced by Folic Acid Antagonist, 4-Aminopteroyl-Glutamic Acid (Aminopterin)The New England Journal of Medicine, 1948